CN112804993A - Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them - Google Patents
Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them Download PDFInfo
- Publication number
- CN112804993A CN112804993A CN201980064766.7A CN201980064766A CN112804993A CN 112804993 A CN112804993 A CN 112804993A CN 201980064766 A CN201980064766 A CN 201980064766A CN 112804993 A CN112804993 A CN 112804993A
- Authority
- CN
- China
- Prior art keywords
- clofazimine
- pharmaceutical composition
- infection
- suspension
- mycobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004287 clofazimine Drugs 0.000 title claims abstract description 214
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 title claims abstract description 214
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000008569 process Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 82
- 208000015181 infectious disease Diseases 0.000 claims abstract description 77
- 239000000725 suspension Substances 0.000 claims abstract description 68
- 239000000443 aerosol Substances 0.000 claims abstract description 57
- 238000011282 treatment Methods 0.000 claims abstract description 54
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 20
- 208000013606 Fungal Lung disease Diseases 0.000 claims abstract description 14
- 241000192125 Firmicutes Species 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims description 138
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 131
- 239000011780 sodium chloride Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 238000000265 homogenisation Methods 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 239000002736 nonionic surfactant Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- 210000004072 lung Anatomy 0.000 claims description 33
- 241000186359 Mycobacterium Species 0.000 claims description 27
- 229960000508 bedaquiline Drugs 0.000 claims description 26
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims description 26
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 23
- 241001508003 Mycobacterium abscessus Species 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 23
- -1 polyoxyethylene Polymers 0.000 claims description 23
- 241000186367 Mycobacterium avium Species 0.000 claims description 21
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 18
- 229960004821 amikacin Drugs 0.000 claims description 17
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 17
- 239000006199 nebulizer Substances 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 208000019693 Lung disease Diseases 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229960005206 pyrazinamide Drugs 0.000 claims description 11
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 11
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 10
- 241000186362 Mycobacterium leprae Species 0.000 claims description 10
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 claims description 10
- 229960002626 clarithromycin Drugs 0.000 claims description 10
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 10
- 230000008021 deposition Effects 0.000 claims description 10
- 229910052733 gallium Inorganic materials 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 229940068968 polysorbate 80 Drugs 0.000 claims description 10
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 claims description 9
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims description 9
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 9
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 9
- 229960002682 cefoxitin Drugs 0.000 claims description 9
- 229960003376 levofloxacin Drugs 0.000 claims description 9
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 9
- 229960003702 moxifloxacin Drugs 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- 229960001225 rifampicin Drugs 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 241000186364 Mycobacterium intracellulare Species 0.000 claims description 8
- 239000007975 buffered saline Substances 0.000 claims description 8
- 239000008151 electrolyte solution Substances 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 238000001238 wet grinding Methods 0.000 claims description 8
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 7
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 230000000510 mucolytic effect Effects 0.000 claims description 7
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 7
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 claims description 6
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 6
- 206010044756 Tuberculous infections Diseases 0.000 claims description 6
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 6
- 229940095731 candida albicans Drugs 0.000 claims description 6
- 239000000076 hypertonic saline solution Substances 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 5
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 claims description 5
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 5
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 claims description 5
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 claims description 5
- WNPVZANXRCPJPW-UHFFFAOYSA-N 5-[isocyano-(4-methylphenyl)sulfonylmethyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C([N+]#[C-])S(=O)(=O)C=2C=CC(C)=CC=2)=C1 WNPVZANXRCPJPW-UHFFFAOYSA-N 0.000 claims description 5
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 claims description 5
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 claims description 5
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 5
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 5
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 claims description 5
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 claims description 5
- 229940011658 asiatic acid Drugs 0.000 claims description 5
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 claims description 5
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 5
- 229940015301 baicalein Drugs 0.000 claims description 5
- 230000032770 biofilm formation Effects 0.000 claims description 5
- 229910052797 bismuth Inorganic materials 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- WXBXVVIUZANZAU-HJWRWDBZSA-N cis-2-decenoic acid Chemical compound CCCCCCC\C=C/C(O)=O WXBXVVIUZANZAU-HJWRWDBZSA-N 0.000 claims description 5
- 239000004148 curcumin Substances 0.000 claims description 5
- 229940109262 curcumin Drugs 0.000 claims description 5
- 235000012754 curcumin Nutrition 0.000 claims description 5
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001484 edetic acid Drugs 0.000 claims description 5
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 150000002334 glycols Chemical class 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 229940117954 naringenin Drugs 0.000 claims description 5
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 5
- 235000007625 naringenin Nutrition 0.000 claims description 5
- YCOFRPYSZKIPBQ-UHFFFAOYSA-N penicillic acid Natural products COC1=CC(=O)OC1(O)C(C)=C YCOFRPYSZKIPBQ-UHFFFAOYSA-N 0.000 claims description 5
- VOUGEZYPVGAPBB-UHFFFAOYSA-N penicillin acid Natural products OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 claims description 5
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229950003776 protoporphyrin Drugs 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 229960000281 trometamol Drugs 0.000 claims description 5
- 229940096998 ursolic acid Drugs 0.000 claims description 5
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 4
- 238000012387 aerosolization Methods 0.000 claims description 4
- 238000000498 ball milling Methods 0.000 claims description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 238000010902 jet-milling Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940124818 soft mist inhaler Drugs 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims 2
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 201000008827 tuberculosis Diseases 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 238000005259 measurement Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 7
- 235000010633 broth Nutrition 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 208000032376 Lung infection Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000003570 air Substances 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010064789 Mycobacterium abscessus infection Diseases 0.000 description 3
- 208000031986 Nontuberculous Mycobacterium Infections Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000001355 anti-mycobacterial effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000008249 pharmaceutical aerosol Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000012383 pulmonary drug delivery Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 2
- 241000186365 Mycobacterium fortuitum Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102100032341 PCNA-interacting partner Human genes 0.000 description 2
- 101710196737 PCNA-interacting partner Proteins 0.000 description 2
- 101150034459 Parpbp gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003926 antimycobacterial agent Substances 0.000 description 2
- 231100001125 band 2 compound Toxicity 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- DGLWHXRTXWIDEE-UHFFFAOYSA-N 1-ethoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCC DGLWHXRTXWIDEE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LKCWBDHBTVXHDL-UHFFFAOYSA-N 4-amino-n-[5-amino-2-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound OC1C(OC2C(C(N)C(O)C(CO)O2)O)C(NC(=O)C(O)CCN)CC(N)C1OC1OC(CN)C(O)C(O)C1O LKCWBDHBTVXHDL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011763 Cystic fibrosis lung Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101100517375 Homo sapiens NTM gene Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000186360 Mycobacteriaceae Species 0.000 description 1
- 208000031998 Mycobacterium Infections Diseases 0.000 description 1
- 241000982184 Mycobacterium abscessus subsp. bolletii 103 Species 0.000 description 1
- 241000254210 Mycobacterium chimaera Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241001479493 Sousa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102000036435 Zincins Human genes 0.000 description 1
- 108091007139 Zincins Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 208000031116 aquarium granuloma Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- VRHMBACMYZITGD-ZXGAWIPVSA-N methanophenazine Chemical compound C1=CC=CC2=NC3=CC(OCC[C@@H](C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=CC=C3N=C21 VRHMBACMYZITGD-ZXGAWIPVSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000022155 mycobacterium avium complex disease Diseases 0.000 description 1
- XLWNLCSWRLEMJR-UHFFFAOYSA-N n-benzylpyrimidin-2-amine Chemical compound C=1C=CC=CC=1CNC1=NC=CC=N1 XLWNLCSWRLEMJR-UHFFFAOYSA-N 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008226 sterile water for inhalation Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000008229 sterile water for irrigation Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000037946 swimming pool granuloma Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine and processes for their preparation, wherein the clofazimine is provided in the form of a suspension. In addition, the present invention provides a pharmaceutical combination containing clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention are useful for the treatment and/or prevention of pulmonary fungal infections and pulmonary infections caused by mycobacteria and other gram-positive bacteria.
Description
This application claims priority to U.S. provisional application No. 62/722,048 filed on 23/8/2018, and U.S. provisional application No. 62/796,322 filed on 25/1/2019, both of which are incorporated herein by reference.
Technical Field
The present invention relates to a pharmaceutical composition for inhalation comprising a therapeutically effective dose of clofazimine, wherein the clofazimine is provided in the form of a suspension; processes for their preparation; as well as uses and methods of treatment comprising them. Furthermore, the present invention provides a pharmaceutical combination containing clofazimine in the form of an aerosol for pulmonary inhalation.
The combinations (combinations) and compositions (combinations) provided by the present invention are useful for the treatment and/or prevention of pulmonary fungal infections and pulmonary infections caused by mycobacteria and other gram positive bacteria.
Background
Clofazimine is a very hydrophobic methanophenazine antibiotic with antimycobacterial and anti-inflammatory activity (Log P7.66) and was first described in 1957. The structural formula is as follows:
the exact mechanism by which clofazimine exerts its antimicrobial effect is not known. However, it is known to preferentially bind mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Other proposed mechanisms of action include membrane damage/destabilization, production of membrane-unstable lysophospholipids, interference of potassium transport, and/or intracellular redox cycling. Although clomazemine has significant activity in vitro against Mycobacterium Tuberculosis (MTB), including multidrug resistant strains, until recently it was generally considered ineffective in treating tuberculosis (see, e.g., Cholo M et al, J Antimicrob chemie, 2012Feb,67(2): 290-8).
Clofazimine is one of the three major drugs recommended by the world health organization for the treatment of leprosy caused by Mycobacterium leprae (Mycobacterium leprae), and has been increasingly used in recent years for the treatment of other mycobacterial infections, such as resistant tuberculosis and infections caused by non-tuberculous mycobacteria (NTM).
Clofazimine is almost insoluble in water and exhibits high membrane permeability, and has therefore been classified as a Biopharmaceutical Classification System (BCS) class II drug.
To overcome the problems associated with poor oral absorption and poor bioavailability of drugs, various strategies such as micronization, nanocrystallization, supercritical fluid recrystallization, spray freeze-drying into liquids, solid dispersions and solutions have been employed in the optimization of oral dosage forms.
Being classified as a BCS class II drug, clofazimine is generally considered an ideal drug candidate for formulating formulations as solid dispersions to enhance oral bioavailability (see, e.g., bhushure et al.ijrpc 2014,4(4), 906-918).
In line with this, clofazimine is usually administered as a microcrystalline suspension in an oily wax matrix to improve oral absorption due to its lipophilic nature. Absorption in humans after oral administration varies widely (45-62%). The adverse effects of clofazimine are dose-dependent and affect mainly the skin, eyes, gastrointestinal tract, and QT-prolonging side effects include reddish-brown discoloration of the skin and conjunctiva, which is gradually reversible after withdrawal. They are the result of chronic systemic accumulation.
Mycobacterium (Mycobacterium) is a genus of actinomycetes, which belongs to the genus Mycobacteria, and a genus of Mycobacteriaceae.
Mycobacteria (Mycobacteria) have a characteristic rod-like shape and a waxy outer shell.
Thus, mycobacteria can be divided into three groups:
mycobacterium tuberculosis (Mycobacterium tuberculosis) complex-the causative agent of tuberculosis
Mycobacterium leprae (Mycobacterium leprae) -causative agent of leprosy
Nontuberculous mycobacteria (NTM), other mycobacteria encompassing all nontuberculous mycobacteria or M.leprae, including Mycobacterium abscessus (Mycobacterium abscessus) complex (MABSC), Mycobacterium avium (Mycobacterium avium) complex (MAC).
Tuberculosis (TB) is an infectious disease caused by bacteria of the mycobacterium tuberculosis complex. TB remains a significant cause of death and morbidity worldwide as one of the most well documented human infectious pathogens, with 1040 new cases of Tuberculosis infection estimated in 2015, and 140 million people dying from active TB (see, e.g., World Health Organization (WHO) Global Tuberculosis Report 2016). In addition to the high prevalence and mortality, the incidence of multidrug-resistant tuberculosis (MDR-TB) is also of increasing concern, with 580000 patients presenting with drug-resistant TB infections now existing in 2015. Complications such as Human Immunodeficiency Virus (HIV) complicate treatment and lead to 120 tens of thousands of TB cases in 2015.
To treat multidrug resistance (MDR) infections, the WHO recommends a 9 to 12 month treatment regimen with a second-line anti-TB drug. These regimens (such as the 9 to 12 month Bangladesh regimen), together with a combination of gatifloxacin, ethambutol, pyrazinamide and clofazimine, treat MDR-TB, which results in a relapse-free cure in 87.9% of patients (see, e.g., Sotgiu, G, et al, "Applicability of the short 'Bangladesh region' in high multidrug-resistant tuboculocations settings", International Journal of Infectious Diseases (2017) 56190-.
Other studies that have investigated the reduction in the duration of TB treatment have shown that there is no clinical benefit after 2 weeks of oral clotrimine (see, e.g., Diacon, A.H., et al, "bacterial Activity of Pyrazinamide and Clofazimine acetone and in compositions with pretomanidine and Bedaquiline," American Journal of research and clinical Care Medicine (2015),191(8), 943) 953). The lack of activity is attributed to the low bioavailability of the drug, as it is theorized that the binding affinity of the drug to circulating serum proteins is high. Although Clofazimine has been empirically demonstrated to be effective in the treatment of MDR-TB and widely-resistant Tuberculosis (XDR-TB), its low bioavailability following systemic administration appears to limit its biological activity in short-term treatments (see, e.g., Swanson, R.V., et al, "Pharmacokinetics and Pharmacodynmics of Clofazimine in a Motor Model of Tuberculosis," Antimicrobial Agents and chemotherapeutics (2015),59 (3056), 3042-.
It is known that treatment of lung infections with Inhaled antibiotics causes higher drug concentrations and reduced adverse effects in the lung compared to systemic delivery (see, e.g., Touw, d.j., et al., "inflammation of infectious in circulatory fibrosis", European Respiratory Journal (1995),8, 1594-. In vivo mouse models have demonstrated that aerosol (aerosolized) administration of clofazimine shows a significant improvement in bacillus (bacillus) clearance in TB infection models compared to oral administration of clofazimine alone for 28 days after treatment initiation alone (see, e.g., Verma, r.k., et al, "inert microbial contamination of microbial bacteria in vitro in rice," Antimicrobial Agents and Chemotherapy (2013),57(2), 1050-. The effect of this short-term improvement may be due to direct delivery of clofazimine to the site of infection in the lungs, resulting in higher concentrations of clofazimine in lung macrophages within the tuberculous granulomas.
Thus, the use of clofazimine aerosol administration in MDR-TB or XDR-TB infected patients should further improve the patient's treatment outcome and possibly shorten the duration of the current treatment regimen.
The group of nontuberculous mycobacteria (NTM), previously known as atypical or ubiquitous mycobacteria, comprises over 150 species. NTM is ubiquitous in nature and exhibits a wide variety. They can be detected in soil, ground, drinking water and food like pasteurized milk or cheese. In general, NTM disease is considered to be less pathogenic. However, they can cause severe disease in humans, especially in humans with compromised immune systems or who have previously suffered from pulmonary disease. Currently, NTM is classified according to its growth rate and divided into Slow Growing (SGM) and fast growing (RGM) mycobacteria.
The slow growing Mycobacterium Avium Complex (MAC) includes the following species: mycobacterium avium, chimeric Mycobacterium (Mycobacterium chimaera) and Mycobacterium intracellulare (Mycobacterium intracellulare), all of which are the most important and most common pathogenic NTM. Like Mycobacterium kansasii (Mycobacterium kansasii), Mycobacterium morganii (Mycobacterium malmoense), Mycobacterium bufonis (Mycobacterium xenopi), Mycobacterium similis (Mycobacterium. simiae), Mycobacterium abscessus, Mycobacterium gordonii (Mycobacterium gordonae), Mycobacterium fortuitum (Mycobacterium fortuitum) and Mycobacterium chelonii (Mycobacterium chelona), they mainly cause pulmonary infections. Marine mycobacteria (Mycobacterium marinum) cause skin and soft tissue infections such as aquarium granuloma (aquaria).
In particular, RGM causes severe, life-threatening chronic lung disease and causes disseminated and often fatal infection. Infections are often caused by contaminated materials and invasive procedures involving catheters, non-sterile surgery, or injection and implantation of foreign bodies. Contact with showerheads and whirlpools also has a report of risk of infection. NTM often leads to opportunistic infections in patients with chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and other immune function compromised patients.
In recent years, the following subspecies have been included: fast growing (RGM) Mycobacterium abscessus group strains (Mycobacterium abscessus complex, MABSC) of Mycobacterium abscessus subspecies (m.a. abscessus), Mycobacterium abscessus and Mycobacterium abscessus are becoming important human pathogens and are associated with significantly higher mortality rates than any other RGM disease.
Mycobacterium abscessus infection in CF patients is particularly problematic because it leads to increased lung destruction and is often untreatable with failure rates as high as 60-66% (see, e.g., Obreg)on-Henao A et al,Antimicrobial Agents and Chemotherapy,November 2015,Vol59,No11,p.6904-6912;Qvist,T.,Pressler,T.,and Katzenstein,TL.,“Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis",Respiratory Research(2014),15(1):pp.41-47)。
Human NTM infection is more associated with the occurrence of the prevalence of human acquired immunodeficiency syndrome. Mycobacteria from the Mycobacterium Avium Complex (MAC) are identified as the major cause of opportunistic infections in patients infected with Human Immunodeficiency Virus (HIV).
Several NTM species are known to form biofilms. Biofilms are small bacterial colonies embedded in an extracellular matrix that provide stability and resistance to human immune mechanisms. In recent years, some species of NTM have been shown to form biofilms, enhancing resistance to disinfection and antimicrobial agents. The assembly of biofilms goes through several stages, including reversible attachment, irreversible attachment, formation of biofilms by bacterial aggregation, tissue and signaling, and finally diffusion. In this process, bacteria form a matrix containing Extracellular Polymeric Substances (EPS), such as polysaccharides, lipids and nucleic acids, to form a complex three-dimensional structure (see, e.g., Sousa s.et al, International Journal of bacteriology 4(2015), 36-43). In particular, mycobacterial EPS is qualitatively different from other biofilms because mycobacteria do not produce exopolysaccharides (see, e.g., Zambrano MM, Kolter R.Mycobacterium bifolims: a great way to hold it to get. cell.2005). Mycobacterial biofilms vary from species to species but may contain mycolic acids, glycopeptide lipids, mycobactyl-diacylglycerols, lipooligosaccharides, lipopeptides and Extracellular DNA (reviewed and originally studied from: Rose SJ, Babraak LM, Bermudz LE (2015) Mycobacterium vacuums strains Exceller DNA that is to Biofilm Format, Structural Integrity, and toll to biology. PLoS ONE). Assembly in biofilms is known to enhance resistance to antimicrobials (see, e.g., Faria s.et al, Journal of Pathogens, Vol 2015, Article ID 809014).
Delivery of aerosolized liposomal amikacin/inhaled amikacin solutions nebulized by a jet nebulizer is suggested as a new method of treating NTM lung infections (Rose s.et al,2014, PLoS ONE, Volume 9, Issue 9, e108703, and Olivier k.et al, Ann Am Thorac Soc Vol 11, No 1, pp.30-35) and Inhalation of anti-TB drug dry powder microparticles is suggested for pulmonary delivery (Cholo M et al, J Antimicrob chemicother.2012feb; 67(2):290-8 and fourier b.and Nettey o.,2015Inhalation Magazine, Verma 2013Antimicrob Agents chemicother).
Initial treatment with parenteral aminoglycosides, tigecycline, and other promising oral antibiotics such as linezolid, delaminanil, and bedaquiline, followed by various combination regimens of inhaled amikacin, and surgical intervention in selected cases, has shown promising results in the treatment of NTM lung disease (Lu Ryu et al. However, the increasing incidence and prevalence of NTM infection, particularly NTM pulmonary disease, and the limited treatment regimens necessitate the development of new dosage forms/pharmaceutical formulations to improve the bioavailability of currently used antibiotics (such as clofazimine). Inhalation can improve efficacy and reduce adverse reactions compared to oral and parenteral treatments.
The combination of Clofazimine and amikacin has shown Synergy against both mycobacterium abscessus and mycobacterium avium In Vitro (see, e.g., van Ingen, j., et al, "In Vitro Synergy between Clofazimine and Am ikacin In Treatment of nonuberculus mycobacteriol Disease," antibiotic Agents and chemitherapy 56(12), 6324. sup. 6327 (2012)). In addition, the synergistic effect of clofazimine and bedaquiline combinations has been shown to be against M.tuberculosis (see, e.g., Cokol, M.et., effective Measurement and differentiation of high-order drug interactions in Mycobacterium tuberculosis, Sciences Advances 2017:3: e170881,11October 2017). The synergistic effect of Clofazimine/Bedaquiline combinations against nontuberculous Mycobacteria abscesses is also shown (Ruth, M.M.et. al., "A Bedaquiline/Clofazimine Combination culture Medium Activity to the Treatment of clinical Reynant Non-Tuberculous Mycobacteria", Journal of antibiotic chemistry (2019), doi.org/10.1093/jac/dky).
Fungal pathogens have become a leading cause of human death. Current evaluations indicate that death due to invasive fungal infections is comparable to more widely known infectious diseases such as tuberculosis. Candida albicans (Candida albicans), Cryptococcus neoformans (Cryptococcus neoformans) and Aspergillus fumigatus (Aspergillus fumigatus) are the most common fungal pathogens in humans. Each of these species causes hundreds of thousands of infections each year, with unacceptably high mortality rates due to poor diagnosis and limited treatment regimens. Chloramphenicol has been shown to be effective against a variety of fungi as a combined agent (see, e.g., Robbins, N., et al, "An antibacterial Combination Matrix ingredients a Ring Pool of An additive organisms at which enzyme Activity against enzyme fungi intermediates Pathologens", Cell Reports 13,1481-1492, November 17,2015). Fungi also function as commensals, colonizers and/or pathogens in cystic fibrosis (see, e.g., Choterimal, S.H.and McElvaney, N.G., "Fungi in The cystic fibrosis lung: Bystans or pathogens.
The low solubility of clofazimine in water results in low oral bioavailability and high microbial resistance, and specific techniques are also needed to dissolve and stabilize drugs formulated in liquid aqueous carriers, such as for aerosolization by a nebulizer, so that aerosol particles achieve more downward lung deposition.
Disclosure of Invention
In one embodiment of the present invention, there is provided a pharmaceutical composition comprising:
(a) a therapeutically effective dose of clofazimine or a pharmaceutically acceptable derivative or salt thereof;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
wherein the clofazimine or a pharmaceutically acceptable derivative or salt thereof is provided in the form of particles in suspension, and
wherein the median particle size of the clofazimine or the pharmaceutically acceptable derivative or salt thereof is less than 5 μm and the D90 is less than 6 μm.
In another embodiment of the invention, the particles of clofazimine or a pharmaceutically acceptable derivative or salt thereof have an average size of less than 2 μm and D90 is less than 3 μm.
In another embodiment of the present invention, there is provided a pharmaceutical composition comprising:
(a) a therapeutically effective dose of clofazimine;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
wherein the clofazimine is provided in the form of particles in suspension,
and is
Wherein the particles of clofazimine have a median size of less than 5 μm and a D90 of less than 6 μm.
In another embodiment of the invention, the particles of clofazimine have a median size of less than 2 μm and D90 is less than 3 μm.
Aerosolization of the compositions of the present invention by a suitable nebulizer provides significantly increased delivery of aerosolized clofazimine into the lower lung (i.e., bronchi, bronchioles and alveoli to the central and lower peripheral lungs), thereby significantly enhancing the therapeutic effect.
Furthermore, the inhalation device should preferably be further adapted for local pulmonary delivery of an aerosol with an optimal particle size distribution for uniform deposition in the lower lung.
Accordingly, the present invention provides an aerosol having aerosol particles of a size that facilitates delivery to the alveoli and bronchioles. Suitable aerodynamic particle sizes for the alveoli and bronchioles are between 1 and 5 μm. Particles larger than this selectively deposit in the upper lungs (i.e. bronchi and trachea) and the mouth and throat (i.e. oropharyngeal region). Thus, the inhalation device is adapted to produce an aerosol having a Mass Median Aerodynamic Diameter (MMAD) in the range of from about 1 to about 5 μm, and preferably in the range of from about 1 to about 3 μm. In another embodiment, the particle size distribution is narrow and the Geometric Standard Deviation (GSD) is less than about 2.5.
Detailed Description
The present invention is based on the unexpected discovery that by pulmonary aerosol administration of clofazimine in suspension, more downward (i.e., deeper) pulmonary deposition of the active agent can be achieved, thereby significantly increasing the bioavailability of the extremely hydrophobic BCS class II agent, which results in significant increased therapeutic efficacy with reduced systemic side effects.
In another aspect, the discovery results in providing improved antibiotic treatment for infections caused by mycobacteria and gram-positive bacteria, particularly NTM lung infections such as opportunistic infections in CF, COPD and immunodeficient patients such as HIV patients.
Furthermore, the present invention aims to overcome the systemic side effects of established oral treatment regimens against gram positive bacterial pulmonary infections, in particular pulmonary TB and NTM infections, as well as to reduce the dose and treatment duration of clofazimine.
It will be understood by those skilled in the art that the present application also discloses each and any combination of the various features disclosed herein.
Definition of
The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the compounds of the present invention and which is not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts due to the presence of amino and/or carboxyl groups or similar groups. Pharmaceutically acceptable acid addition salts may be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic, propionic, naphthoic, oleic, palmitic, pamoic (embonic), stearic, glycolic, pyruvic, oxalic, maleic, malonic, succinic, fumaric, tartaric, citric, ascorbic, glucoheptac, glucuronic, lactic, lactobionic, tartaric, benzoic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, salicylic, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, histidine, arginine, lysine, benzylaminopyrimidine, N-methyl-glucamine, and ethanolamine, among others. Other acids include dodecyl sulfuric acid, naphthalene-1, 5-disulfonic acid, naphthalene-2-sulfonic acid, and saccharin.
According to the invention, in addition to the free base, preference is given to using the salts of methanesulfonic acid, maleic acid, isonicotinic acid, nicotinic acid, malonic acid and salicylic acid, particularly preferably clofazimine mesylate.
The term "pharmaceutically acceptable derivative" as used herein, for example, refers to the compounds disclosed in US9,540,336, the disclosure of US9,540,336 being incorporated herein in its entirety. Furthermore, derivatives are described in Lu, Y., Zhen, M., Wang, B., Fu, L., ZHao, W., Li, P., Xu, J., Zhu, H., Jin, H., Yin, D.Huang, H., Upton, AM.AndMa, Z., "clone Analogs with electronic acquisition experience experimental batteries and reduced position for access" Antimicrobial Agents and chemistry (2011),55(11): pp.5185-5193. Furthermore, the term "pharmaceutically acceptable derivative" of a compound is, for example, a prodrug of said compound. Generally, a prodrug is a derivative of a compound that, when administered, provides the active form of the compound. These derivatives may be, for example, esters or amides of carboxyl groups, esters of carboxyl groups of hydroxyl groups, or phosphate esters of hydroxyl groups.
"therapeutically effective amount", "therapeutically effective dose", or "pharmaceutically effective amount" refers to the amount of clofazimine or a pharmaceutically acceptable salt or derivative thereof disclosed herein that has a therapeutic effect. The dose of clofazimine that can be used in the treatment is a therapeutically effective amount. Thus, as used herein, therapeutically effective amounts refer to those amounts of clofazimine that are judged by clinical trial results and/or model animal infection studies to produce the desired therapeutic effect.
The amount and daily dosage of clofazimine can be routinely determined by one of skill in the art and will vary depending on several factors, such as the particular microbial strain involved. The amount may also depend on the patient's height, weight, sex, age and medical history. For prophylactic treatment, a therapeutically effective amount is an amount effective to prevent a microbial infection.
A "therapeutic effect" alleviates one or more symptoms of an infection to some extent and includes curing the infection. By "curing" is meant that the symptoms of active (active) infection are eliminated, and excess members of viable microorganisms, including those involved in the infection, are completely or substantially eliminated, at or below the detection threshold of traditional measurements. However, even after healing, the infection may have some long-term or permanent effects (such as extensive tissue damage). As used herein, "therapeutic effect" is defined as a statistically significant reduction in bacterial load, the appearance of drug resistance, or an improvement in the symptoms of infection in a host as measured by human clinical outcome or animal studies.
As used herein, the terms "treatment", "treating", or "treating" refer to the administration of a pharmaceutical composition/combination for prophylactic and/or therapeutic purposes.
The term "prophylactic treatment" refers to the treatment of a patient who has not yet been infected, but who is susceptible to or at risk of a particular infection. The term "therapeutic treatment" refers to administering a treatment to a patient already suffering from an infection. Thus, in a preferred embodiment, the treatment is (for therapeutic or prophylactic purposes) administration of a therapeutically effective amount of clofazimine to the mammal.
Unless otherwise indicated herein, the term "inhalation" refers to pulmonary inhalation.
The term "infection" as used herein refers to a pulmonary infection, unless otherwise indicated herein.
Unless otherwise indicated, the term "substantially" when used in reference to the purity of a compound means 95% purity or greater of the compound.
Unless otherwise indicated, the term "suitable particle size" refers to the particle size of clofazimine in the composition, or in a composition that provides the desired therapeutic effect when administered to a patient.
The term "suitable concentration" refers to the concentration of a component in a composition or combination that provides a pharmaceutically acceptable composition or combination, unless otherwise indicated.
Pharmaceutical compositions and combinations
The following grades of water are particularly suitable for use in the present invention: sterile purified water, sterile water for injection, sterile water for irrigation, sterile water for inhalation (USP) and corresponding grades of water according to e.g. the european pharmacopoeia or the national formulary.
The aqueous electrolyte solution used as an aqueous liquid carrier according to the present invention may further comprise sodium chloride, potassium chloride, lithium chloride, magnesium chloride, calcium chloride, or mixtures thereof.
The aqueous liquid carrier is preferably an isotonic saline solution (0.9% NaCl, which corresponds to about/about 150mM NaCl, preferably 154mM NaCl).
Chlorine-derived Zincin has been demonstrated to exist in at least four polymorphic forms (see, e.g., Bannigan, et al, "Investigation into the Solution and Solution Properties of Known and Novel Polymorphs of the Antimicrobial biological Molecule Clofazimine", Crystal. growth Des.2016, (16) (12), pp.7240-7250). Clofazimine may exist in the triclinic form FI, the monoclinic form FII, and the orthorhombic form FIII. Another form of FIV is visible only at high temperatures.
Thus, in a further embodiment of the present invention, there is provided a pharmaceutical composition comprising:
(a) a therapeutically effective dose of clofazimine;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
wherein the clofazimine is provided in the form of particles in suspension,
and is
Wherein the particles of clofazimine have a median size of less than 5 μm and a D90 of less than 6 μm, preferably a median size of less than 2 μm and a D90 of less than 3 μm, and wherein the clofazimine is provided in one or more polymorphic forms selected from the group consisting of triclinic FI, monoclinic FII and orthorhombic FIII, and mixtures of these forms. In another embodiment, clofazimine is provided substantially in the orthorhombic form FIII.
In a further embodiment of the invention, there is provided a pharmaceutical composition according to any of the composition embodiments described herein, wherein the non-ionic surfactant is selected from polysorbate 20 (e.g., polysorbate 20)20) Polysorbate 60 (e.g. sodium chloride)60) Polysorbate 80 (e.g. Polysorbate)80) Stearyl alcohol, polyethylene glycol derivatives of hydrogenated castor oils having a hydrophilic-lipophilic balance of from 14 to 16 (for exampleRH 40), polyethylene glycol derivatives of hydrogenated castor oil with a hydrophilic lipophilic balance of 15 to 17 (e.g. polyethylene glycol derivatives of hydrogenated castor oil with a hydrophilic lipophilic balance of 15 to 17RH 60), sorbitol monolaurate (e.g. R60)20) Sorbitol monopalmitate (e.g. sorbitol monopalmitate)40) Sorbitol monostearate (e.g. sorbitol monostearate)60) Polyoxyethylene (20) oleyl alcohol ether (e.g. methanol)020) Polyoxyethylene (20) cetyl ether (e.g. polyethylene oxide)58) Polyoxyethylene (10) cetyl ether (e.g. polyethylene oxide)C10) Polyoxyethylene (10) oleyl alcohol ether (e.g. methanol)O10), polyoxyethylene (100) stearyl ether (e.g., ethyl stearyl etherS100), polyoxyethylene (10) stearyl ether (e.g.S10), polyoxyethylene (20) stearyl ether (e.g. polyoxyethyleneS20), polyoxyethylene (4) lauryl ether (e.g. sodium lauryl ether)L4), polyoxyethylene (20) cetyl ether (e.g. polyethylene oxide)93) Polyoxyethylene (2) cetyl ether (e.g. polyethylene oxide)S2), caprylocaproyl polyoxy-8 glycerides (e.g. caprylocaproyl polyoxy-8 glycerides)) Polyethylene glycol (20) stearate (e.g. Myrj)TM49) Polyethylene glycol (40) stearate (e.g. Myrj)TMS40), polyethylene glycol (100) stearate (e.g. Myrj)TMS100), polyethylene glycol (8) stearate (e.g. Myrj)TMS8) and polyethylene glycol 40 stearate (e.g., Myrj)TM52) And mixtures thereof.
In another embodiment of the present invention, there is provided a pharmaceutical composition according to any of the composition embodiments described herein, wherein the non-ionic surfactant is polysorbate 80 and wherein the aqueous liquid carrier is distilled water, a hypertonic salt solution, or an isotonic salt solution. In another embodiment of the present invention, a pharmaceutical composition is provided wherein the hypertonic saline solution is 1% to 7% (w/v) sodium chloride. In a further embodiment of the invention, there is provided a pharmaceutical composition wherein the non-ionic surfactant is ultra pure polysorbate 80 (e.g. polysorbate 80(Hx2) by NOF) and wherein the aqueous liquid carrier is an isotonic saline solution.
In another embodiment of the present invention there is provided a pharmaceutical composition according to any one of the composition embodiments described herein, wherein the osmolality of the composition is in the range of 200-700 mOsm/kg. In another embodiment, the osmolality of the composition is in the range of 300-400 mOsm/kg.
In a further embodiment of the present invention there is provided a pharmaceutical composition according to any of the composition embodiments described herein, wherein the non-ionic surfactant comprises from 0.001% to 5% (v/v) of the total composition and the amount of clofazimine comprises from 0.1% to 20% (w/v) of the total composition.
In another embodiment of the present invention, there is provided a pharmaceutical composition according to any one of the composition embodiments described herein, wherein the pharmaceutical composition is prepared by a process comprising the steps of:
(1) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size,
(2) adjusting the pH of the suspension obtained in (1) to a pH between pH 5.5 and pH 7.5, and
(3) adjusting the sodium chloride concentration to a suitable concentration, an
(4) Osmolality was adjusted to the appropriate level.
In a further embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In another embodiment, the homogenization in step (1) is performed by high pressure homogenization, high shear homogenization, wet milling, ultrasonic homogenization, or a combination of these methods. In another aspect, the homogenization of clofazimine is performed in multiple homogenization steps. In another embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In a further embodiment of the present invention, there is provided a pharmaceutical composition according to any one of the composition embodiments described herein, wherein the pharmaceutical composition is prepared by a process comprising the steps of:
(1) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size,
(2) separating the clofazimine to obtain the clofazimine,
(3) adding clofazimine into a nonionic surfactant and water,
(4) adjusting the pH of the suspension obtained in (3) to a pH between pH 5.5 and pH 7.5, and
(5) the sodium chloride concentration was adjusted to a suitable concentration.
In a further embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In a further embodiment, the homogenization in step (1) is performed by high pressure homogenization, high shear homogenization, wet milling, ultrasonic homogenization or a combination of these methods. In another embodiment, the homogenization of clofazimine is performed in multiple homogenization steps. In another embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In a further embodiment, there is provided a pharmaceutical composition according to any of the composition embodiments described herein, wherein the composition is prepared by a process comprising the steps of:
(1) micronizing the clofazimine to obtain clofazimine with a proper particle size,
(2) adding clofazimine into a nonionic surfactant and water,
(3) adjusting the pH of the suspension obtained in (2) to a pH between pH 5.5 and pH 7.5, and
(4) the sodium chloride concentration was adjusted to a suitable concentration.
In a further embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride.
In another embodiment, micronization of clofazimine is performed by jet milling, spray drying, ball milling, or supercritical fluid processing. In another embodiment, the micronization of clofazimine is performed in multiple micronization steps. In another embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In a further embodiment, there is provided a pharmaceutical composition according to any of the composition embodiments described herein, wherein the composition is prepared by a process comprising: a suspension of clofazimine in a non-ionic surfactant, water containing a suitable concentration of sodium chloride, is homogenized and the pH of the suspension has been adjusted to a pH between pH 5.5 and pH 7.5 to obtain clofazimine of a suitable particle size. In a further embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In further embodiments, homogenization is performed by high pressure homogenization, high shear homogenization, wet milling, ultrasonic homogenization, or a combination of these steps. In another embodiment, the homogenization of clofazimine is performed in multiple homogenization steps. In another embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In another embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the composition embodiments described herein, comprising the steps of:
(1) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size,
(2) adjusting the pH of the suspension obtained in (1) to a pH between pH 5.5 and pH 7.5, and
(3) adjusting the sodium chloride concentration to a suitable concentration, an
(4) Osmolality was adjusted to the appropriate level.
In another embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In further embodiments, homogenization is performed by high pressure homogenization, wet milling, ultrasonic homogenization, or a combination of these methods. In a further embodiment, the homogenization of clofazimine is performed in multiple homogenization steps. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In another embodiment, a process for preparing any of the pharmaceutical composition embodiments described herein is provided, wherein,
(1) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size,
(2) separating the clofazimine to obtain the clofazimine,
(3) adding clofazimine into a nonionic surfactant and water,
(4) adjusting the pH of the suspension obtained in (3) to a pH between pH 5.5 and pH 7.5, and
(5) the sodium chloride concentration was adjusted to a suitable concentration.
In another embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In further embodiments, homogenization is performed by high pressure homogenization, wet milling, ultrasonic homogenization, or a combination of these methods. In a further embodiment, the homogenization of clofazimine is performed in multiple homogenization steps. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In a further embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the pharmaceutical composition embodiments described herein, comprising the steps of:
(1) micronizing the clofazimine to obtain clofazimine with a proper particle size,
(2) adding clofazimine into a nonionic surfactant and water,
(3) adjusting the pH of the suspension obtained in (2) to a pH between pH 5.5 and pH 7.5, and
(4) the sodium chloride concentration was adjusted to a suitable concentration.
In another embodiment, the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride. In further embodiments, micronization of clofazimine is performed by jet milling, spray drying, ball milling, or supercritical fluid processing. In a further embodiment, the micronization of clofazimine is performed in multiple micronization steps. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In another embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In another embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the composition embodiments described herein, comprising homogenizing a suspension of clofazimine in water containing a suitable concentration of sodium chloride, a non-ionic surfactant, and the pH of the suspension has been adjusted to a pH between pH 5.5 and pH 7.5 to obtain clofazimine of a suitable particle size. In another embodiment, the pH is 7.4 and a suitable concentration of sodium chloride is 154mM sodium chloride. In further embodiments, homogenization is performed by high pressure homogenization, wet milling, ultrasonic homogenization, or a combination of these methods. In a further embodiment, the homogenization of clofazimine is performed in multiple homogenization steps. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and D90 of less than 6 μm. In a further embodiment, clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and D90 of less than 3 μm.
In a further embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the composition embodiments described herein, comprising the steps of: (a) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size; (b) adjusting the pH of the resulting suspension to a pH between pH 5.5 and pH 7.5; (c) adjusting the sodium chloride concentration to a suitable concentration, and (d) adjusting the osmolality to a suitable level; and wherein, steps (b), (c) and (d), may be (b), (c), (d); (b) (d), (c); (c) (b), (d); (c) (d), (b); (d) (b), (c); or (d), (c) and (b) occur sequentially.
In another embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the composition embodiments described herein, comprising the steps of: (a) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size; (b) separating clofazimine; (c) adding clofazimine to a nonionic surfactant and water; (d) adjusting the pH of the resulting suspension to a pH between pH 5.5 and pH 7.5; and (e) adjusting the sodium chloride concentration to a suitable concentration; and wherein steps (d) and (e) may be (d), (e); or (e) and (d) occur sequentially.
In another embodiment, there is provided a method of preparing a pharmaceutical composition according to any of the composition embodiments described herein, comprising the steps of: (a) micronizing clofazimine to obtain clofazimine of suitable particle size, and (b) adding clofazimine to a nonionic surfactant, water containing a suitable concentration of sodium chloride, and adjusted to a pH between pH 5.5 and 7.5.
In another embodiment of the present invention, there is provided a pharmaceutical combination in aerosol form for inhalation prepared by nebulizing a composition according to any of the composition embodiments described herein using a nebulizing device selected from the group consisting of an ultrasonic nebulizer, an electrospray nebulizer, a vibrating membrane nebulizer, a jet nebulizer, and a mechanical soft mist inhaler, and
wherein the mass median aerodynamic diameter of the aerosol particles produced by the nebulisation means is from 1 to 5 μm. In a further embodiment, the aerosol for inhalation is for lower lung deposition. In another embodiment, the atomizing device exhibits an output rate of 0.1 to 1.0 ml/min. In another embodiment, the total inspired volume is between 1ml to 5 ml.
In another embodiment, there is provided a pharmaceutical composition according to any of the composition embodiments described herein for use in combination with an agent that disperses and/or disrupts biofilm, a mucolytic and/or mucoactive agent, and/or an agent that reduces biofilm formation selected from the group consisting of: nebulized 4-7% hypertonic saline solution, metaperiodate, sodium lauryl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth thiols (bismuths), ethylenediaminetetraacetic acid, gentamicin-loaded phosphatidylcholine-modified gold nanoparticles, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides. In another embodiment, the composition for use is administered before, simultaneously with or after the administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof.
In another embodiment, there is provided a pharmaceutical combination according to any of the combination embodiments described herein for use in combination with an agent for dispersing and/or disrupting biofilm, a mucolytic and/or mucoactive agent, and/or an agent for reducing biofilm formation selected from the group consisting of: nebulized 4-7% hypertonic saline solution, metaperiodate, sodium lauryl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth mercaptane, ethylene diamine tetraacetic acid, gentamicin-loaded phosphatidylcholine-modified gold nanoparticles, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides. In another embodiment, the combination for said use is for administration of a combination of the compositions of the invention before, simultaneously with or after administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampicin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof. In another embodiment, the composition is administered prior to, simultaneously with, or after administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, and acamicin, and mixtures thereof. In further embodiments, the composition is administered prior to, simultaneously with, or after the administration of bedaquiline or a pharmaceutically acceptable salt or derivative thereof.
In another embodiment, there is provided a pharmaceutical composition according to any one of the composition embodiments described herein for use in the treatment and/or prevention of a pulmonary infection caused by mycobacteria or other gram-positive bacteria. In a further embodiment, the infection is caused by a species of mycobacterium selected from the group consisting of nontuberculous mycobacteria and Mycobacterium tuberculosis complex and combinations thereof. In a further embodiment, the non-tuberculous mycobacterium is selected from the group consisting of mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus, and mycobacterium leprae and combinations thereof. In another embodiment, the infection is an opportunistic infection selected from the group consisting of MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in cystic fibrosis patients. In another embodiment, the composition for use is administered prior to, simultaneously with, or subsequent to the administration of an agent of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate, and mixtures thereof. In another embodiment, the composition is administered prior to, simultaneously with, or after administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, and acamicin, and mixtures thereof. In further embodiments, the composition is administered prior to, simultaneously with, or after the administration of bedaquiline or a pharmaceutically acceptable salt or derivative thereof.
In another embodiment, a pharmaceutical combination according to any of the combination embodiments described herein is provided for the treatment and/or prevention of a pulmonary infection caused by mycobacteria or other gram-positive bacteria. In a further embodiment, the infection is caused by a species of mycobacterium selected from the group consisting of nontuberculous mycobacteria and Mycobacterium tuberculosis complex and combinations thereof. In a further embodiment, the non-tuberculous mycobacterium is selected from the group consisting of mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus, and mycobacterium leprae and combinations thereof. In another embodiment, the infection is an opportunistic infection selected from the group consisting of MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in cystic fibrosis patients. In another embodiment, the combination for said use is for administration of a composition of the invention before, simultaneously with or after administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof. In another embodiment, the combination for said use is for administering a composition of the invention before, simultaneously with or after the administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, and acamicin, and mixtures thereof. In another embodiment, the combination for said use is for administration of a composition of the invention before, simultaneously with or after the administration of bedaquiline or a pharmaceutically acceptable salt or derivative thereof.
In another embodiment, a system is provided for providing antibiotic activity in treating or providing prophylaxis against a pulmonary infection caused by a mycobacterium or other gram-positive bacterium, wherein the system comprises:
1) an aerosolized pharmaceutical combination comprising:
(a) a therapeutically effective dose of clofazimine;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
and
2) an atomizer is arranged on the bottom of the water tank,
wherein the clofazimine is provided in the form of a suspension,
and is
Wherein the mass median aerodynamic diameter of the aerosol particles produced by the nebulisation means is from 1 to 5 μm.
In a further embodiment, a pharmaceutical composition according to any of the composition embodiments described herein is provided for use in the treatment and/or prevention of pulmonary fungal infection or clostridium difficile or a combination thereof. In another embodiment, there is provided a pharmaceutical composition according to any one of the composition embodiments described herein for use in the treatment and/or prevention of a pulmonary fungal infection. In a further embodiment, the pulmonary fungal infection is candida albicans or aspergillus fumigatus or a combination thereof.
In a further embodiment, a pharmaceutical combination according to any one of the combination embodiments described herein is provided for use in the treatment and/or prevention of a pulmonary fungal infection or clostridium difficile or a combination thereof. There is provided a combination of drugs according to any one of the combination embodiments described herein for use in the treatment and/or prevention of a pulmonary fungal infection. In a further embodiment, the pulmonary fungal infection is candida albicans or aspergillus fumigatus or a combination thereof.
In another embodiment, there is provided a method of treating or preventing a pulmonary infection in a patient in need thereof, comprising administering by inhalation a composition according to any of the composition embodiments described herein. In another embodiment, the infection is caused by a species of mycobacterium selected from the group consisting of nontuberculous mycobacteria and Mycobacterium tuberculosis complex and combinations thereof. In another embodiment, the non-tuberculous mycobacterium is selected from the group consisting of mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus, and mycobacterium leprae and combinations thereof. In a further embodiment, the infection is an opportunistic infection selected from MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in cystic fibrosis patients.
In a further embodiment, there is provided a method of treating or preventing a pulmonary infection caused by mycobacteria or other gram-positive bacteria in a patient in need thereof comprising administering by inhalation a composition according to any of the composition embodiments described herein before, simultaneously with or after administering an agent selected from the group consisting of a pharmaceutically acceptable salt of bedaquiline or a derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof. In another embodiment, the agent is bedaquiline or amikacin. In a further embodiment, the agent is bedaquiline.
Particle size and distribution
The therapeutic effect of aerosolized therapy depends on the deposited dose and its distribution. Aerosol particle size is one of the important variables that define the lung deposition dose and the aerosol distribution of the drug.
Generally, inhaled aerosol particles deposit by one of two mechanisms: impaction (usually dominating larger aerosol particles) and sedimentation (dominating smaller aerosol particles). Collisions occur when the momentum of inhaled aerosol particles is large enough that the particles do not follow the airflow and encounter physiological surfaces. In contrast, when very small aerosol particles traveling with the inhaled air stream sink due to gravity to encounter physiological surfaces, settling occurs primarily in the lower lung.
Pulmonary drug delivery can be achieved by inhalation of aerosols through the mouth and throat. Aerosol particles having an aerodynamic diameter greater than about 5 μm do not typically reach the lungs; instead, they tend to impact the back of the throat and are swallowed and may be absorbed orally. Aerosol particles of about 3 to about 5 μm in diameter are small enough to reach the upper to middle lung region (conducting airways), but too large to reach the alveoli. Smaller aerosol particles, i.e., about 0.5 to about 3 μm, are able to reach the alveolar region. Aerosol particles less than about 0.5 μm in diameter tend to be exhaled during tidal (tidal) breathing, but may also be deposited in the alveolar region by breath-holding.
The aerosols used in pulmonary drug delivery consist of aerosols of various particle sizes, and therefore statistical descriptors are used. Aerosols used in pulmonary drug delivery are generally described by their Mass Median Diameter (MMD), i.e., half of the mass is contained in aerosol particles larger than the MMD and half of the mass is contained in aerosol particles smaller than the MMD. For particles of uniform density, Volume Median Diameter (VMD) may be used interchangeably with MMD. VMD and MMD were determined by laser diffraction. The width of the distribution is described by the Geometric Standard Deviation (GSD). However, deposition of aerosol particles in the respiratory tract is more accurately described by the aerodynamic diameter of the particles, and therefore mass median aerodynamic diameters are typically used. MMAD determinations are made by inertial impaction or time-of-flight measurements. For aqueous particles, VMD, MMD and MMAD should be the same. However, if humidity is not controlled when the aerosol passes through the impactor, the MMAD measurement will be less than MMD and VMD due to dehydration. For purposes of description, the VMD, MMD and MMAD measurements are considered to be under controlled conditions so that the descriptions of VMD, MMD and MMAD will be comparable.
Nevertheless, for the purposes of description, the aerosol particle size of the aerosol particles will be given in MMAD as measured at room temperature with a Next Generation Impactor (NGI) according to the usp convention. Disclosed in Process review <601> Aerools, Nasal Sprays, used-Dose Inhalers, and Dry Powder Inhalers, Pharmacopeial Forum (2003), Volume Number 29, pages 1176-.
According to the invention, the particle size of the aerosol is optimized to maximize the deposition of clofazimine at the site of infection and to maximize tolerability. Aerosol particle size can be expressed in terms of Mass Median Aerodynamic Diameter (MMAD). Large particles (e.g., MMAD > 5 μm) tend to deposit in the extrathoracic and upper airways because they are too large to pass in bends in the airways. Intolerance (e.g., cough and bronchospasm) may be caused by large particle deposition in the upper airway.
Thus, according to a preferred embodiment, the MMAD of the aerosol should be less than about 5 μm, preferably between about 1 and 5 μm, more preferably below 3 μm (<3 μm).
However, a guided breathing strategy may be employed that allows larger particles to pass through the extrathoracic and upper airways and deeper into the lungs than when tidal breathing, which will increase aerosol deposition in the middle and lower lungs. The pilot breathing strategy may be as slow as 100 ml/min. Therefore, when used with a guided breathing strategy, the preferred MMAD of the aerosol should be less than about 10 μm.
Another factor of equal importance (in addition to aerosol particle size) is the particle size and size distribution of the solid particles, in this case clofazimine. The size of the solid particles in a given aerosol particle must be smaller than the aerosol particle in which it is contained. Larger aerosols may contain one or more solid particles. Furthermore, when handling dilute suspensions, a majority of the aerosol particles may not contain solid particles.
Thus, it is desirable that the solid drug particles be significantly smaller than the MMAD of the aerosol particles. For example, if the MMAD of the aerosol particles is 3 μm, then the desired solid particles are 1 μm or less.
Another consideration is that, for example, using a vibrating mesh nebulizer, the formulation is pumped through the holes in the plate, breaking the suspension into droplets. Thus, the solid particles must also be smaller than these pores to pass through.
The solid particle size in the suspension can be given by the average size of the particles and the distribution of the particles. The D90 value indicates that 90% of the particles in the suspension have an average size or less.
Atomizer
For aqueous and other non-pressurized liquid systems, a variety of nebulizers (including small volume nebulizers) are available for aerosolizing the formulation. Compressor-driven nebulizers employ jet technology and use compressed air to produce a liquid aerosol. Such devices are available from, for example, health Technologies, inc; invacare, Inc.; mountain Medical Equipment, inc; pari rapidity, inc; mada Medical, inc; Puritan-Bennet; schuco, inc., DeVilbiss Health Care, inc.; and Hospitak, Inc. Ultrasonic nebulizers rely on mechanical energy in the form of piezoelectric crystal vibration to produce respirable droplets and are commercially available from, for example, Omron Heathcare, Inc. and DeVilbiss Health Care, Inc. Vibrating mesh nebulizers rely on piezoelectric or mechanical pulses to produce respirable droplets. Other examples of atomizers for use with the clofazimine described herein are described in U.S. Pat. Nos. 4,268,460; 4,253,468, respectively; 4,046,146, respectively; 3,826,255, respectively; 4,649,911, respectively; 4,510,929, respectively; 4,624,251, respectively; 5,164,740, respectively; 5,586,550, respectively; 5,758,637, respectively; 6,644,304, respectively; 6,338,443, respectively; 5,906,202, respectively; 5,934,272, respectively; 5,960,792, respectively; 5,971,951, respectively; 6,070,575, respectively; 6,192,876, respectively; 6,230,706, respectively; 6,349,719, respectively; 6,367,470, respectively; 6,543,442, respectively; 6,584,971, respectively; 6,601,581; 4,263,907, respectively; 5,709,202, respectively; 5,823,179, respectively; 6,192,876, respectively; 6,644,304, respectively; 5,549,102, respectively; 6,083,922, respectively; 6,161,536, respectively; 6,264,922; 6,557,549, respectively; and 6,612,303, which are incorporated herein by reference in their entirety. Commercial examples of atomizers that can be used with the clofazimine compositions described herein include Respirgard, produced by Aerogen Pro andgo; produced by AradigmAnd AERx EssenceTM(ii) a Manufactured by Respironics, incFreeway Freedom TMSidesstream, Ventstream and I-neb; and PARI produced by PARI GmbHPARIAnd e-Flow7 m. A further non-limiting example is disclosed in US 6,196,219.
According to the present invention, the pharmaceutical composition may preferably be nebulized using a nebulizing device selected from the group consisting of an ultrasonic nebulizer, an electronic spray nebulizer, a vibrating membrane nebulizer, a jet nebulizer or a mechanical soft mist inhaler.
Preferably, the device controls the patient's inspiratory flow rate through an electrical or mechanical process.
In another preferred embodiment, the device is triggered to generate an aerosol by inhalation by the patient, such as with an AKITA device.
Preferred (commercially available) examples of the above-described atomizers/devices for use in accordance with the present invention are Vectura fox, Pari eFlow, Pari Trek S, Philips Innospire mini, Philips Innospire Go, Medspray device, Aeroneb Go, Aerogen Ultra, Respironics aerobe, Akita, Medspray ecomlst, and Respimat.
For the treatment and/or prophylaxis of
The pharmaceutical compositions and pharmaceutical combinations (aerosol, aerosolized formulations) and systems according to the present invention are intended for use in the treatment and/or prevention of pulmonary infections caused by mycobacteria or other clofazimine-sensitive bacteria, such as Staphylococcus aureus (including methicillin-resistant and vancomycin intermediate resistant strains), Streptococcus pneumoniae (Streptococcus pneumoniae) and Enterococcus spp. The pharmaceutical compositions and combinations of the present invention may also be used to treat and/or prevent fungal infections of the lung.
Administration of clofazimine (dosing)
According to the invention, the pharmaceutical composition is delivered by nebulization of about 1-5ml, preferably 1-2ml, of the pharmaceutical composition of the invention.
Thus, the target fill dose is about 1-5ml (corresponding to 20-100mg of clofazimine) based on about 20mg/ml of clofazimine concentration in the pharmaceutical composition.
The daily lung dose of clofazimine administered according to the invention, i.e. the dose deposited in the lungs, is about 5-10mg, which corresponds to a nominal dose (device dose) of 15-30mg in case of mycobacterium abscessus infection.
It will be appreciated that the skilled person will routinely adjust the pulmonary dose of clofazimine to be administered (and hence the fill/nominal dose/volume to be aerosolized) based on the Minimum Inhibitory Concentration (MIC) of clofazimine for the corresponding bacterial strain as is well known in the art.
Depending on the frequency of administration (once or twice daily), daily lung doses will be assigned accordingly.
According to the invention clofazimine is administered once or twice daily, resulting in a total daily lung dose of about 5 to 10 mg.
It will be apparent to those skilled in the art that the above amounts relate to clofazimine free base and that the dosages of the derivatives and salts must be adjusted accordingly to the MIC of the corresponding compound and strain.
Mucolytic and/or biofilm modifying agents
In order to reduce sputum viscosity and disrupt existing biofilm during aerosol treatment, treatment and/or prevention according to the present invention may include additional administration of mucolytic and/or biofilm disrupting agents.
These agents may be prepared in fixed combination form or administered simultaneously or subsequently to the clofazimine-containing pharmaceutical composition/aerosol combination according to the invention.
The agent for dispersing/disrupting biofilm, mucolytic and/or mucoactive agent and/or agent that reduces biofilm formation used according to the invention is selected from: nebulized 4-7% hypertonic saline solution, metaperiodate, sodium lauryl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth mercaptane, ethylene diamine tetraacetic acid, gentamicin-loaded phosphatidylcholine-modified gold nanoparticles, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides.
In addition, other pharmaceutically active agents may also be used in combination with the pharmaceutical composition/aerosol combination of the present invention. Such active agents may be selected from bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and p-aminosalicylate, and mixtures thereof.
These agents may be prepared in a fixed combination, or administered prior to, simultaneously with, or subsequently to the clofazimine-containing pharmaceutical composition/aerosol combination according to the invention.
Examples
The present invention is described and the best mode contemplated for carrying out various aspects of the present invention is set forth. Embodiments in accordance with the present invention are those which fall within the scope of the claims herein.
Experiment of
The following exemplary compositions and combinations are prepared according to the methods described herein.
Example 1
200mg of clofazimine (in triclinic form I), 90mg of sodium chloride and 9.5ml of water were mixed twice in an Ultra-Turrax homogenizer at a speed of 10000rpm, 5 minutes each time. 0.5ml of polysorbate 80(NOF Hx2) was added. An ultrasonic probe (Branson Digital Sonifier) was usedTM250D in conjunction with Bandelin Sonoplus Probe MS73) seven times with an amplitude of 70% for 3 minutes each. The volume was adjusted to 10ml with water. The suspension was filtered through VWR fold qualitative filter paper (303, particle retention 5-13 μm, size: 150mm) to give the composition of example 1. The median particle size of clofazimine for the composition of example 1 was 3.9 μm and D90 was 6.7 μm. The concentration of clofazimine was measured by 280nm uv/vis spectrophotometry, calibrated using a stock solution of clofazimine (stock) diluted in mobile phase at 1mg/ml, and found to be 7.16 mg/ml.
The compositions of example 1 are shown in Table 1
TABLE 1
Preparation of orthorhombic III-type clofazimine
A slurry of clofazimine (10g) in toluene (20ml) was stirred in an oil bath at 40 ℃ for 72 hours at 800rpm with a magnetic stirrer. The solid portion of the slurry was collected by crucible filtration and dried in a vacuum oven at a maximum temperature of 40 ℃. 8.64g of substantially pure (98%) clofazimine in orthorhombic form III was obtained.
Example 2
6g of clofazimine in orthorhombic form III was added in 100ml of water containing 0.5% polysorbate 80(NOF Hx2) and 0.6% sodium chloride and pre-micronized using Ultra-Turrax at 10000rpm for about 40 seconds. A pre-formulation was prepared by adding 0.6% sodium chloride to water to give a volume of 300 ml. 300ml of this suspension was added to the inlet of a homogenizer (M-110EH-30 microfluidizer (Microfluidics, Westwood, Mass., USA)) and a pre-homogenization step was performed by circulating the suspension through the H30Z chamber at 5000psi for 15 minutes. Subsequently, a second H10Z chamber was installed in series with the first chamber and the suspension was further homogenized for 23 minutes at 25000 psi. Particle size analysis using HORIBA LA 950 showed a median particle size of 0.83 μm and a D90 value of 1.17 μm. The concentration of the clofazimine is 16.05mg/ml through 280nm ultraviolet/visible spectrum measurement by using the calibration of a 1mg/ml clofazimine stock solution diluted by a mobile phase.
The compositions of example 2 are shown in Table 2
TABLE 2
Example 3
The composition of example 3 was produced in the H30Z-G10Z configuration using a suspension of clofazimine (crystal modified orthorhombic form III) in water, sodium chloride and polysorbate 80 solution treated with M-110EH-30 microfluidizer processor (chambers: H30Z and G10Z) operating at 28250psi for 30 minutes, resulting in clofazimine particles with a median particle size of 1.28 μ M and D90 below 2 μ M.
The composition of example 3 is shown in Table 3
TABLE 3
Viscosity measurement
The viscosity of the composition of example 3 was tested using an STRESSTECH rheometer in stress control mode. A double gap geometry is used and the spindle is rotated continuously to ensure that the particles remain suspended during the temperature point. Viscosity measured at 20 ℃,25 ℃ and 30 ℃ respectively across 0.01, 0.05 and 0.1Pa stress. Two separate loads were performed to obtain the average viscosities shown in table 4 below.
TABLE 4
Animal models and efficacy testing
The compositions of the present invention have been tested for their ability to inhibit the growth of clinical NTM species in a mouse model of acute in vivo pulmonary infection to obtain preliminary data to establish clofazimine concentration levels in lung tissue following direct respiratory delivery as opposed to systemic administration. Two separate mouse models were used to study lung NTM infection depending on the bacterial species of interest. In the tests, strains of M.avium 2285 and M.abscessus 103 were used (see filing of strains details (9 months 2014) to "Phylogenetic analysis of Mycobacterium species using the world genes" Hazbon M.H., Riojas M.A., Damon A.M., Alalade R., Cantwell B.J., Monaco A., King S., Sohrabi A.) of the EMBL/GenBank/DDBJ database). These two were previously used in the literature as Models for NTM infection (Obregon-Henao et al 2015 antisense Agents Chemother; and Chan et al animal Models of Non-Tuberculus Mycobacterium Infections, Mycobacterium Dis 2016).
In vivo safety studies in Balb/C mice:
to ensure in vivo safety and tolerability, 6-8 week old Balb/C female mice were obtained from Charles River. Mice were allowed to rest for one week prior to dosing. For each clofazimine dose, three healthy mice were given a total of three doses every other day. At 10.0, 5.01 and 2.51mg/kg of clofazimineThe composition of example 1 was administered to mice. By passingAerosol intratracheal administration, 3 healthy mice were dosed with these compounds, 3 doses every other day.
Clofazimine was found to be safe at 20mg/kg doses (gavage, 200 μ l). The composition of example 1 showed no toxicity at the highest dose tested (10.0 mg/kg; 35 μ l intratracheal 0.2506 mg/dose). Thus, at a dose of 10.0mg/kg, the formula I composition is considered safe and well tolerated.
Determination of the minimum inhibitory concentration
By usingHinton (mh) broth (cation adjustment) Minimal Inhibitory Concentration (MIC) testing was performed by microbhank (microboth) dilution with calcium and magnesium concentrations to the concentrations recommended in CLSI standard M7-a7(Becton Dickinson). MIC testing was also performed by microtissues dilution using 7H9 broth (Sigma-Aldrich). The reason for compound screening using MH and 7H9 broths was that anti-mycobacterial compounds have been shown to exhibit different MIC activities, depending on the broth used in the MIC assay. M. abscessus was grown in ambient air at 35-37 ℃ for 3 days (depending on the bacterial strain) on 7H11 agar plates (Sigma-Aldrich), and M.avium was grown in ambient air at 37 ℃ for 21-30 days on 7H11 agar plates (Sigma-Aldrich).
Colony Forming Units (CFU) were removed from agar plates and placed in MH or 7H9 broth containing 0.05% tween-80 and grown in ambient air at 35-37 ℃ until the Optical Density (OD) absorbance measured after 3 days of growth (M. abscessus) or 12 days (M. avium) was 0.08-0.1(0.5McFarland standard). Confirmation was then made by preparing a bacterial cell suspension in saline solution, matching (OD)0.08-0.1(0.5McFarland standard). Stock solutions of compounds were prepared by suspending the compounds in DMSO at a concentration of 1.28mg/ml and immediately used to test the range 64-0.062 pg/ml. Thereafter, 180. mu.l of the broth (MH or 7H9) was added to the first column of the 96-well plate, and 100. mu.l of the broth was added to the remaining columns of the 96-well plate. Mu.l of the compound stock was added to the wells of the first column and diluted continuously. Finally, 100 μ l NTM cell suspension was added to all wells except the medium only control well. QC reagents specific to each organism 1) bacteria only negative control 2) media only negative control 3) clarithromycin positive drug control.
M. abscessus was analyzed for OD on the third day, while M.avium was analyzed for OD on day 12. After these measurements, the plates were analyzed using the resazurin microtiter plate assay. Briefly, the method uses addition of resazurin (7-hydroxy-3H-phenothiazin-3-one 10-oxide) to 96-well plates. Resazurin is a blue dye that itself is weakly fluorescent until irreversibly reduced to pink and highly red fluorescent resorcinol. In MIC assays, it is used as a redox indicator to determine the viability of bacterial cells.
The analysis was performed in triplicate. The composition of example 1 was stored at 4 ℃ for 2 months and then analyzed for #1, #2 at 4 months and #3 at 5 months.
Minimum inhibitory concentration in the Presence and absence of CF sputum
The minimum inhibitory concentration analysis was performed as described above.
To investigate the effect of Cystic Fibrosis (CF) patient sputum on the antimicrobial activity of Clofazimine (CFZ) and the composition of example 1, sputum was collected from patients who had not received antibiotic treatment within the previous 48 hours and disinfected by exposure to uv light to clear endogenous bacteria. After sterilization, mycobacterium abscessus, mycobacterium avium, mycobacterium intracellulare and chimeric mycobacterium were cultured in 10% CF sputum prior to MIC testing. The MIC of the composition of example 1 was measured according to the same CLSI protocol as described above in the presence and absence of cystic fibrosis patient sputum. All studies were performed in duplicate.
Table 5 shows MIC values for clofazimine and the composition of example 1 in the presence and absence of sputum.
TABLE 5
The results in Table 5 show that the MICs of clofazimine and the composition of example 1 are consistent for a range of non-tuberculous mycobacterial species.
These data indicate that the composition of example 1 shows effective in vitro activity against mycobacterium abscessus and mycobacterium avium and is stable for at least this period of time.
Mouse model of mycobacterium abscessus in SCID mice
SCID female mice 6-8 weeks old were ordered from Charles River. Mice were rested one week prior to infection.
Prior to use, stock solutions of M.abscessus strain 103 were frozen in 1ml aliquots and stored at-80 ℃. For infection, aliquots were thawed, broken 20 times with a 1ml luer-lok syringe fitted with a 26g needle, and diluted in sterile 1 × PBS.
The acute SCID mouse model received 1X 106Non-invasive intratracheal instillation of lung infections in CFU/mouse (M.abscessus strain 103).
3 mice were sacrificed 1 day post infection and bacterial uptake was determined. Whole lung, spleen and liver were extracted and homogenized in 4.5ml of 1 x PBS. Homogenization serial dilutions were made at a dilution of 1:10 and dilutions (0-1-2-3-4-5-6-7) were placed on 7H11 agar plates. The plates were placed in a 32 ℃ dry air incubator (depending on the strain) for 7 days.
The composition of example 1, 10.0mg/kg, was administered by the pulmonary route(35 μ l) and clofazimine (gavage), amikacin (subcutaneous) in a volume of 200 μ l per mouse, starting on day 2 post-infection and continuing for 8 days every other day.
Mice were sacrificed 2 days after the last dose of compound. All groups of 6 mice (untreated control, clofazimine (gavage), the composition of example 1, and amikacin treated mice) were sacrificed and the bacterial load was determined. The lung homogenate was placed at 0-1-2-3-4-5-6-7, the spleen homogenate at 0-1-2-3-4-5-6-7, and the liver homogenate at 0-1-2-3-4-5-6-7.
A Log10 protection value of at least 0.60 indicates that the activity is statistically significant. CFU was first converted to logarithms for statistical analysis, then evaluated by one-way analysis of variance, and then multiple comparisons of variance were performed by one-way Tukey test (GraphPad Prism analysis software). At the 95% confidence level, the difference was considered significant.
Table 6 shows the mean Log after Mycobacterium abscessus infection in SCID mice10CFU data and mean Standard Error (SEM), where "n" is the total number of animals in the group at time of sacrifice.
TABLE 6
The data in table 6 show that treatment with the composition of example 1 resulted in the greatest reduction in bacterial recovery in the lungs and spleen of animals infected with mycobacterium abscessus. This reduction in bacteria was statistically improved compared to amikacin or oral clofazimine treatment.
Mouse model of M.avium infection in Beige mice
6-8 week old Beige female mice were ordered from Charles River. Mice were rested one week prior to infection.
The acute Beige mouse model received 1X 108Colony Forming Units (CFU)/ml (mycobacterium avium strain 2285rough) of non-invasive aerosol exposure to lung infection. Before use, the working stock of M.avium strain 2285 was frozen in 1ml aliquots and stored at-80 ℃. For theInfection, aliquots were thawed, broken 20 times with a 1ml luer-lok syringe fitted with a 26g needle, and diluted in sterile 1 x Phosphate Buffered Saline (PBS).
3 mice were sacrificed on day 1 and day 7 post-infection and bacterial uptake was determined. Whole lung, spleen and liver were extracted, homogenized in 4.5ml of 1 x PBS and diluted to 1: 10. Dilutions (0-1-2-3-4-5-6-7) were placed on 7H11/OADC, TSA and charcoal agar plates and incubated in a dry air incubator (depending on the strain) at 32 ℃ for 30 days.
The composition of example 1, 10.0mg/kg, was administered by the pulmonary route(35. mu.l) and clofazimine (gavage) was administered in a volume of 200. mu.l per mouse, starting on day 7 post-infection and continuing for 10 days every other day.
Mice were sacrificed 5 days after the last dose of compound. All groups of 6 mice (untreated control, clofazimine (gavage), and the composition of example 1 mice) were sacrificed and bacterial load was determined. The lung homogenate was placed at 0-1-2-3-4-5-6-7, the spleen homogenate at 0-1-2-3-4-5-6-7, and the liver homogenate at 0-1-2-3-4-5-6-7.
Log10 protection values of at least 0.60 indicate that the activity is statistically significant. The CFU is first converted to logarithms for statistical analysis, then evaluated by one-way analysis of variance, and then subjected to multiple comparative analysis of variance by one-way Tukey test (SigmaStat software program). At the 95% confidence level, the difference was considered significant.
Table 7 shows the mean Log after Mycobacterium avium infection in Beige mice10CFU data.
TABLE 7
The data in table 7 show that treatment with the composition of example 1 results in a greater reduction of bacterial recovery in the lungs and spleen of animals infected with mycobacterium avium.
Chronic Beige mouse model
Beige mice 6 to 8 weeks old were rested one week prior to infection. On day 0, mice received 1X 108CFU of Mycobacterium avium 2285rough lung infection. 3 mice were sacrificed on day 1 and 6 mice were sacrificed on day 27 and bacterial uptake and pre-treatment bacterial load were determined. Whole lung, spleen and liver were extracted, homogenized in 4.5ml of 1 × PBS, and placed on 7H11 and charcoal agar plates at a dilution of (0-1-2-3-4-5-6-7). The plates were placed in a 37 ℃ dry air incubator for 25 to 30 days.
The remaining infected Beige mice were treated every other day for 14 treatments starting on day 28. The animals received one of the following treatments: physiological saline solution (35. mu.l); clofazimine (oral gavage, 20mg/kg, 200 μ l); the composition of example 1 (IT,10mg/kg,35μl)。
mice were sacrificed on day 57 (two days after final treatment). The plates were placed in a 37 ℃ dry air incubator for 30 days.
CFU's were first converted to logarithms for statistical analysis, then evaluated by one-way analysis of variance, and then multiple comparative analysis of variance was performed by one-way Tukey test. At the 95% confidence level, the difference was considered significant.
Table 8 shows the mean Log after chronic infection with Mycobacterium avium of Beige mice10CFU data.
TABLE 8
These data indicate that clofazimine hardly penetrates granuloma-like structures formed by established "chronic" animal NTM infection models. It appears that the compositions of the invention do not present the same problems and are able to maintain anti-mycobacterial activity even after the infection has been well established.
Effect of the composition of example 3 on Barrier integrity and inflammation following in vitro Exposure to Lung epithelial cells
Cell survival rate
Survival of lung epithelial cells was assessed under two in vitro conditions using three different cell types: calu-3; a549; and hAELVI cells. Under "submerged conditions" (i.e. in transwell)TMIn cell culture medium on a plate) or "gas-liquid interface" simulated conditions (ALI), and cell culture medium is removed from the topside of the cells. Calu-3 cells were exposed to three doses of the example 3 composition (10%, 50% or 100%) for 4 hours under "immersion conditions". To assess cell viability, cells were stained using acridine orange/propidium iodide (AO/PI) staining to distinguish live/dead cells. Red fluorescence indicates cell death.
Macrophage uptake
THP-1 cells differentiated into macrophage-like cells after 3 days of incubation with 124ng/ml phorbol 12-myristic acid 13 acetate (M MA). Once the cells had matured, they were exposed to the composition of example 3 (diluted 1:200 in Hank buffered saline (HBSS)) for 4 hours. Cells were stained by AO/PI as described above to determine cell viability after exposure.
Transepithelial electrical resistance (TEER) measurement
In transwellTM3460 at 1 × 105Cells/well were seeded with Calu-3 cells and left for 12 days to grow to confluence. According to the manufacturer's instructionsTEER measurements were performed using EVOM2(World Precision Instruments, Friedberg, Germany). After inoculation, Calu-3 cells were exposed to saline solution (negative control) or the composition of example 3 (concentration: 20mg/ml, 10mg/ml or 20. + -.2 mg/ml). Cells were exposed for 2 to 4 hours before TEER was measured.
Production of inflammatory cytokines
Differentiated THP-1 cells (dTHP-1) were exposed to the composition of example 3 for 4 hours or 24 hours (1:200HBSS dilution). HBSS exposure alone was used as a negative control and Lipopolysaccharide (LPS) (100ng/ml) was administered as a positive control.
After incubation, supernatants were removed from cells after either t 4 hours or 24 hours and the supernatants were combined. The pooled supernatant samples were subjected to enzyme-linked immunosorbent assay (ELISA). According to the manufacturer's instructions, the use of separate TNF alpha IL-6, IL-8 ELISA kit.
Statistical analysis was performed by one-way analysis (ANOVA) of variables and by subsequent Tukey post hoc tests. It was statistically significant to determine a probability value < 0.05.
Results
Under "submerged" conditions, the composition of example 3 did not cause a visual decrease in cell viability in 4 hours of culture at any applied concentration.
Under "ALI" conditions, three different cell types (Calu-3, a549, and haeldi cells) were studied at three different time points (five hours, two days, and seven days). Little or no cytotoxicity was observed at 4 hours in any cells, and little or no cytotoxicity was observed at 2 days in Calu-3 cells. Some toxicity was observed on days 2 and 7 in a549 cells and on day 7 in Calu-3 cells. Technical limitations do not allow quantification of cell death.
For macrophage uptake, differentiated THP-1 cells were incubated for 4 hours at 1:200HBSS to determine macrophage survival after exposure. The composition of example 3 did not induce cell death, but showed uptake of clofazimine by macrophages.
For TEER measurements, Calu-3 cells were exposed to HBSS or three concentrations of the composition of example 3 for 4 hours and TEER measurements were sampled at different time points throughout the exposure process. A > 50% reduction in TEER at any given time point compared to the control group is considered a significant loss of barrier integrity.
The composition of example 3 had no effect on barrier integrity after one hour exposure to Calu-3 cells. An exposure of 20mg/ml resulted in a significant (i.e.. gtoreq.50%) reduction after two hours. At a concentration of 10mg/ml, a slight decrease (i.e. 25-35%) was shown at all time points after two hours. Exposure of 2mg/ml did not show any reduction in barrier function throughout the study period.
Inflammatory cytokine production
The positive control LPS performed as expected in this model. The composition of example 3 showed no significant change in cytokines at any time point studied.
The results are shown in table 9.
Cytokine production following dTHP-1 cell exposure
Table 9 (. p < 0.05)
In vivo safety and tolerability
In 6-8 weeks, pld Balb/C female mice were given three doses every other day. The composition of example 1 was administered to mice at doses of clofazimine of 10.0, 5.01, and 2.51 mg/kg. The composition was passed through a volume of 35. mu.l/mouseAerosol Intratracheal (IT) administration. After instillation, mice were observed at 10 minutes, 1, 2, and 4 hours after dosing, and then daily.
Table 10 shows the general observations after administration. "BAR" means that the animal is cheerful, active and responsive.
Watch 10
Table 11 shows the body weights of the animals over the three day period tested.
TABLE 11
These data indicate that there was no significant change in body weight during the three day treatment period.
These results indicate that the compositions of the invention are well tolerated at the doses tested.
Claims (75)
1. A pharmaceutical composition comprising:
(a) a therapeutically effective dose of clofazimine or a pharmaceutically acceptable derivative or salt thereof;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
wherein the clofazimine or a pharmaceutically acceptable derivative or salt thereof is provided in the form of particles in suspension, and
wherein the median particle size of the clofazimine or the pharmaceutically acceptable derivative or salt thereof is less than 5 μm and the D90 is less than 6 μm.
2. The pharmaceutical composition of claim 1, wherein the particles of clofazimine or a pharmaceutically acceptable derivative or salt thereof have an average size of less than 2 μ ι η and D90 is less than 3 μ ι η.
3. A pharmaceutical composition comprising:
(a) a therapeutically effective dose of clofazimine;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
wherein the clofazimine is provided in the form of particles in suspension,
and is
Wherein the particles of clofazimine have a median size of less than 5 μm and a D90 of less than 6 μm.
4. The pharmaceutical composition of claim 3, wherein the particles have an average size of less than 2 μm and a D90 of less than 3 μm.
5. Pharmaceutical composition according to any of claims 3 or 4, wherein the clofazimine is provided in one or more polymorphic forms selected from the triclinic form FI, the monoclinic form FII and the orthorhombic form FIII and mixtures of these forms.
6. The pharmaceutical composition of claim 5, wherein said clofazimine is provided substantially in an orthorhombic form FIII.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the non-ionic surfactant is selected from polysorbate 20, polysorbate 60, polysorbate 80, stearyl alcohol, polyethylene glycol derivatives of hydrogenated castor oil having a hydrophilic-lipophilic balance of 14 to 16, polyethylene glycol derivatives of hydrogenated castor oil having a hydrophilic-lipophilic balance of 15 to 17, sorbitol monolaurate, sorbitol monopalmitate, sorbitol monostearate, polyoxyethylene (20) oleyl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (100) stearyl ether, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (4) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (2) cetyl ether, caprylocaproyl polyoxy-8 glyceride, Polyethylene glycol (20) monostearate, polyethylene glycol (40) stearate, polyethylene glycol (100) stearate, polyethylene glycol (8) stearate, and polyethylene glycol 40 stearate, and mixtures thereof.
8. The pharmaceutical composition according to any one of claims 1 to 7,
wherein the nonionic surfactant is polysorbate 80, and
wherein the aqueous liquid carrier is distilled water, a hypertonic salt solution, or an isotonic salt solution.
9. The pharmaceutical composition of claim 8, wherein the hypertonic salt solution is 1% to 7% (w/v) sodium chloride.
10. The pharmaceutical composition of claim 8, wherein the non-ionic surfactant is ultra-pure polysorbate 80, and wherein the aqueous liquid carrier is an isotonic salt solution.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the osmolality of the composition is 200-700 mOsm/kg.
12. The pharmaceutical composition according to any one of claims 1 to 10, wherein the osmolality of the composition is 300-400 mOsm/kg.
13. The pharmaceutical composition according to any one of claims 1 to 10,
the nonionic surfactant comprises 0.001% to 5% (v/v) of the total composition, and
the clofazimine is present in an amount of 0.1% to 20% (w/v) of the total composition.
14. The pharmaceutical composition according to any one of claims 1 to 13, prepared by a process comprising the steps of:
(1) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size,
(2) adjusting the pH of the suspension obtained in (1) to a pH between pH 5.5 and pH 7.5, and
(3) adjusting the sodium chloride concentration to a suitable concentration and
(4) adjusting the osmolality to a suitable level.
15. The pharmaceutical composition according to any one of claims 1 to 13, prepared by a process comprising the steps of:
(1) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size;
(2) separating the clofazimine, and then separating,
(3) adding the clofazimine into the nonionic surfactant and water,
(4) adjusting the pH of the suspension obtained in (3) to a pH between pH 5.5 and pH 7.5, and
(5) the sodium chloride concentration is adjusted to a suitable concentration.
16. The pharmaceutical composition according to any one of claims 1 to 13, prepared by a process comprising the steps of:
(1) micronizing the clofazimine to obtain clofazimine with a proper particle size,
(2) adding the clofazimine into the nonionic surfactant and water,
(3) adjusting the pH of the suspension obtained in (2) to a pH between pH 5.5 and pH 7.5, and
(4) the sodium chloride concentration is adjusted to a suitable concentration.
17. The pharmaceutical composition according to any one of claims 1 to 13, which is prepared by a process comprising: a suspension of clofazimine in a nonionic surfactant, water containing a suitable concentration of sodium chloride, is homogenized to obtain clofazimine of a suitable particle size, and the pH of the suspension has been adjusted to a pH between pH 5.5 and pH 7.5.
18. The pharmaceutical composition of any one of claims 14, 15 or 16, wherein the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride.
19. The pharmaceutical composition of claim 17, wherein the pH is 7.4 and the suitable concentration of sodium chloride is 154mM sodium chloride.
20. The pharmaceutical composition of claim 16, wherein micronization of said clofazimine is by jet milling, spray drying, ball milling, or supercritical fluid processing.
21. The pharmaceutical composition according to any one of claims 14, 15, 17 or 19, wherein the homogenization in step (1) is performed by high pressure homogenization, high shear homogenization, wet milling, ultrasonic homogenization, or a combination of these methods.
22. The pharmaceutical composition of any one of claims 14, 15, 17, 18, 19 or 21, wherein homogenization of the clofazimine is performed in multiple homogenization steps.
23. The pharmaceutical composition according to any one of claims 16 or 20, wherein micronization of said clofazimine is carried out in multiple micronization steps.
24. The pharmaceutical composition of any one of claims 14 to 23, wherein the clofazimine of suitable particle size is a particle with an average size of less than 5 μ ι η and D90 of less than 6 μ ι η.
25. The pharmaceutical composition of any one of claims 14 to 23, wherein the clofazimine of suitable particle size is a particle having an average size of less than 2 μ ι η and D90 of less than 3 μ ι η.
26. A pharmaceutical combination in aerosol form for inhalation prepared by aerosolization of a composition according to any one of claims 1 to 25 by an aerosolization device selected from the group consisting of an ultrasonic nebulizer, an electrospray nebulizer, a vibrating membrane nebulizer, a jet nebulizer and a mechanical soft mist inhaler, and
wherein the mass median aerodynamic diameter of the aerosol particles produced by the nebulisation device is from 1 to 5 μm.
27. The pharmaceutical combination of claim 26, wherein the aerosol for inhalation is for lower lung deposition.
28. A pharmaceutical composition according to any one of claims 1 to 25 for use in combination with an agent that disperses and/or disrupts biofilm, a mucolytic and/or mucoactive agent, and/or an agent that reduces biofilm formation selected from the group consisting of: nebulized 4-7% hypertonic saline solution, metaperiodate, sodium lauryl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth mercaptane, ethylene diamine tetraacetic acid, gentamicin-loaded phosphatidylcholine-modified gold nanoparticles, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides.
29. A pharmaceutical combination according to any one of claims 26 or 27 for use in combination with an agent that disperses and/or disrupts biofilm, a mucolytic and/or mucoactive agent, and/or an agent that reduces biofilm formation selected from the group consisting of: nebulized 4-7% hypertonic saline solution, metaperiodate, sodium lauryl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth mercaptane, ethylene diamine tetraacetic acid, gentamicin-loaded phosphatidylcholine-modified gold nanoparticles, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomeric peptides, gallium mesoporphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides.
30. The pharmaceutical composition according to any one of claims 1 to 25 for use in the treatment and/or prevention of pulmonary infections caused by mycobacteria or other gram-positive bacteria.
31. The pharmaceutical combination according to any one of claims 26 or 27 for use in the treatment and/or prevention of pulmonary infections caused by mycobacteria or other gram-positive bacteria.
32. The pharmaceutical composition of claim 30, wherein the infection is caused by a species of mycobacterium selected from the group consisting of nontuberculous mycobacteria and a tuberculous mycobacteria complex and combinations thereof.
33. The pharmaceutical combination for use according to claim 31, wherein the infection is caused by a species of mycobacterium selected from the group consisting of nontuberculous mycobacteria and a complex of mycobacterium tuberculosis, and combinations thereof.
34. The pharmaceutical composition for the use according to claim 32, wherein the non-tuberculous mycobacterium is selected from the group consisting of mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus, and mycobacterium leprae, and combinations thereof.
35. The pharmaceutical combination for use according to claim 33, wherein the non-tuberculous mycobacterium is selected from the group consisting of mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus and mycobacterium leprae, and combinations thereof.
36. The pharmaceutical composition for use according to claim 32, wherein the infection is an opportunistic infection selected from MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immunodeficiency syndrome.
37. The pharmaceutical combination for use according to claim 33, wherein the infection is an opportunistic infection selected from MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immunodeficiency syndrome.
38. The pharmaceutical composition for the use according to claim 36, wherein the infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
39. The pharmaceutical combination according to claim 37, wherein the infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
40. A system for providing antibiotic activity in the treatment or provision of prophylaxis of pulmonary infections caused by mycobacteria or other gram positive bacteria, wherein the system comprises:
1) an aerosolized pharmaceutical combination comprising:
(a) a therapeutically effective dose of clofazimine;
(b) a nonionic surfactant having a hydrophilic-lipophilic balance value of greater than 10; and
(c) an aqueous liquid carrier selected from the group consisting of water, isotonic saline solution, buffered saline solution, and aqueous electrolyte solution,
and
2) an atomizer is arranged on the bottom of the water tank,
wherein the clofazimine is provided in the form of a suspension,
and is
Wherein the mass median aerodynamic diameter of the aerosol particles produced by the system is from 1 to 5 μm.
41. Use according to any one of claims 28 to 39, wherein the atomising device exhibits an output rate of 0.1-1.0 ml/min.
42. The use of any one of claims 28 to 39, or 41, wherein the total inhaled volume is between 1 and 5 ml.
43. The use of any one of claims 28, 30, 32, 34, 36 or 38, wherein the composition is administered prior to, concurrently with, or subsequent to the administration of an agent selected from bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate, and mixtures thereof.
44. The use of any one of claims 29, 31, 33, 35, 37 or 39, wherein the combination is administered prior to, simultaneously with or subsequent to the administration of an agent selected from bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof.
45. The pharmaceutical composition according to any one of claims 1 to 25 for use in the treatment and/or prevention of pulmonary fungal infection or clostridium difficile, or a combination thereof.
46. The pharmaceutical combination according to any one of claims 26, 27, 29, 31, 33, 35, 37 or 39 for use in the treatment and/or prevention of pulmonary fungal infection or Clostridium difficile, or a combination thereof.
47. The pharmaceutical composition according to claim 45, for use in the treatment and/or prevention of a pulmonary fungal infection.
48. The pharmaceutical combination according to claim 46 for use in the treatment and/or prevention of pulmonary fungal infections.
49. The pharmaceutical composition of any one of claims 45 or 47, wherein the pulmonary fungal infection is Candida albicans or Aspergillus fumigatus, or a combination thereof.
50. The pharmaceutical combination according to any one of claims 46 or 48, wherein the pulmonary fungal infection is Candida albicans or Aspergillus fumigatus, or a combination thereof.
51. The use of claim 43, wherein the composition is administered prior to, concurrently with, or subsequent to the administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, and acamicin, and mixtures thereof.
52. The use of claim 43, wherein the composition is administered prior to, concurrently with, or subsequent to the administration of bedaquiline or a pharmaceutically acceptable salt or derivative thereof.
53. A method of treating or preventing a pulmonary infection in a patient in need thereof, comprising administering by inhalation a composition according to any one of claims 1 to 25.
54. The method of treatment or prevention according to claim 53, wherein the infection is caused by a species of Mycobacterium selected from the group consisting of non-Mycobacterium tuberculosis and Mycobacterium tuberculosis complex and combinations thereof.
55. A method of treatment or prevention according to claim 54, wherein the non-tuberculous mycobacteria are selected from M.
56. A method of treatment or prevention according to claim 53, wherein the infection is an opportunistic infection selected from MAC lung disease and non-tuberculous infection in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immunodeficiency syndrome.
57. The method of treatment or prevention according to claim 56, wherein the infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
58. A method of treating or preventing a pulmonary infection caused by mycobacteria or other gram positive bacteria in a patient in need thereof comprising administering by inhalation a composition according to any one of claims 1 to 25 before, simultaneously with or after administering an agent selected from the group consisting of pharmaceutically acceptable salts of bedaquiline or its derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampicin, moxifloxacin, levofloxacin and p-aminosalicylate and mixtures thereof.
59. The method of treating or preventing according to claim 58, wherein the agent is bedaquiline or amikacin.
60. A method of treatment or prophylaxis according to claim 59, wherein the agent is bedaquiline.
61. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of:
(1) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size;
(2) adjusting the pH of the suspension obtained in (1) to a pH between pH 5.5 and pH 7.5, and
(3) adjusting the sodium chloride concentration to a suitable concentration, an
(4) Adjusting the osmolality to a suitable level.
62. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of:
(1) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size;
(2) separating the clofazimine, and then separating,
(3) adding the clofazimine into a nonionic surfactant and water,
(4) adjusting the pH of the suspension obtained in (3) to a pH between pH 5.5 and pH 7.5, and
(5) the sodium chloride concentration is adjusted to a suitable concentration.
63. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of:
(1) micronizing the clofazimine to obtain clofazimine with a proper particle size,
(2) adding the clofazimine into a nonionic surfactant and water,
(3) adjusting the pH of the suspension obtained in (2) to a pH between pH 5.5 and pH 7.5, and
(4) the sodium chloride concentration is adjusted to a suitable concentration.
64. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising homogenizing a suspension of clofazimine in a non-ionic surfactant, in water containing a suitable concentration of sodium chloride to obtain clofazimine of suitable particle size, and the pH of the suspension has been adjusted to a pH between pH 5.5 and pH 7.5.
65. The method of any one of claims 61, 62, or 63, wherein the pH is adjusted to 7.4 and the sodium chloride concentration is adjusted to 154mM sodium chloride.
66. The method of claim 64, wherein the pH is 7.4 and the suitable concentration of sodium chloride is 154mM sodium chloride.
67. The method of claim 63, wherein micronizing of said clofazimine is performed by jet milling, spray drying, ball milling, or supercritical fluid processing.
68. The process of any one of claims 61, 62, 64, or 66, wherein the homogenizing in step (1) is performed by high pressure homogenization, wet milling, ultrasonic homogenization, or a combination of these methods.
69. The method of any one of claims 61, 62, 64, 65, 66 or 68, wherein homogenization of said clofazimine is performed in multiple homogenization steps.
70. The process of any one of claims 63 or 20, wherein micronization of said clofazimine is carried out in a plurality of micronization steps.
71. The method of any one of claims 61-70, wherein the clofazimine of a suitable particle size is a particle having an average size of less than 5 μm and a D90 of less than 6 μm.
72. The method of any one of claims 61-70, wherein the clofazimine of a suitable particle size is a particle having an average size of less than 2 μm and a D90 of less than 3 μm.
73. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of: (a) homogenizing a suspension of clofazimine, a nonionic surfactant and water to obtain a suspension containing clofazimine of a suitable particle size; (b) adjusting the pH of the resulting suspension to a pH between pH 5.5 and pH 7.5; (c) adjusting the sodium chloride concentration to a suitable concentration, and (d) adjusting the osmolality to a suitable level; and wherein steps (b), (b) and (d), may be (b), (c), (d); (b) (d), (c); (c) (b), (d); (c) (d), (b); (d) (b), (c); or (d), (c) and (b) occur sequentially.
74. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of: (a) homogenizing the suspension of clofazimine and non-aqueous liquid to obtain a suspension containing clofazimine of suitable particle size; (b) separating the clofazimine; (c) adding the clofazimine to a nonionic surfactant and water; (d) adjusting the pH of the resulting suspension to a pH between pH 5.5 and pH 7.5; and (e) adjusting the sodium chloride concentration to a suitable concentration; and wherein steps (d) and (e) may be (d), (e); or (e) and (d) occur sequentially.
75. A process for preparing a pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of: (a) micronizing clofazimine to obtain clofazimine of suitable particle size, and (b) adding said clofazimine to a non-ionic surfactant, water containing a suitable concentration of sodium chloride, and having adjusted its pH to a pH between pH 5.5 and pH 7.5.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862722048P | 2018-08-23 | 2018-08-23 | |
US62/722,048 | 2018-08-23 | ||
US201962796822P | 2019-01-25 | 2019-01-25 | |
US62/796,822 | 2019-01-25 | ||
PCT/US2019/025538 WO2020040818A1 (en) | 2018-08-23 | 2019-04-03 | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112804993A true CN112804993A (en) | 2021-05-14 |
Family
ID=69591424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980064766.7A Pending CN112804993A (en) | 2018-08-23 | 2019-04-03 | Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3840737A1 (en) |
JP (2) | JP7377259B2 (en) |
KR (1) | KR20210090607A (en) |
CN (1) | CN112804993A (en) |
AU (1) | AU2019324330A1 (en) |
CA (1) | CA3109572A1 (en) |
WO (1) | WO2020040818A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114507189A (en) * | 2021-12-08 | 2022-05-17 | 余述南 | Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3157104A1 (en) * | 2019-11-06 | 2021-05-14 | Thomas Hofmann | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them |
CN111634940B (en) * | 2020-05-27 | 2021-10-29 | 中国地质大学(武汉) | Preparation method of simple substance gold uniformly-loaded titanate nano material |
CN112521339A (en) * | 2020-11-20 | 2021-03-19 | 山西立业制药有限公司 | Preparation method of chlorphenazine |
US11793808B2 (en) * | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
CN115737560A (en) * | 2022-12-27 | 2023-03-07 | 四川农业大学 | Acid-responsive nitric oxide/active oxygen nano generator and preparation method thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826255A (en) | 1972-06-22 | 1974-07-30 | Hudson Oxygen Therapy Sales Co | Intermittent positive pressure breathing manifold |
YU41046B (en) | 1974-08-22 | 1986-10-31 | Schering Ag | Medicine inholating device |
US4268460A (en) | 1977-12-12 | 1981-05-19 | Warner-Lambert Company | Nebulizer |
US4253468A (en) | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
US4263907A (en) | 1979-05-14 | 1981-04-28 | Lindsey Joseph W | Respirator nebulizer |
US4510929A (en) | 1982-04-30 | 1985-04-16 | Bordoni Maurice E | Disposable radioactive aerosol inhalation apparatus |
US4649911A (en) | 1983-09-08 | 1987-03-17 | Baylor College Of Medicine | Small particle aerosol generator for treatment of respiratory disease including the lungs |
US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
DK0540775T3 (en) | 1991-11-07 | 1997-08-25 | Ritzau Pari Werk Gmbh Paul | Especially for use in inhalation therapy apparatus |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
DE69633222T2 (en) | 1995-02-24 | 2005-09-08 | Elan Pharma International Ltd. | NANOPARTICLE DISPERSIONS CONTAINING AEROSOLS |
US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
US6349719B2 (en) | 1997-02-24 | 2002-02-26 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
WO1999017754A1 (en) | 1997-10-08 | 1999-04-15 | Sepracor Inc. | Dosage form for aerosol administration |
DE69834210T2 (en) | 1997-11-19 | 2007-01-04 | Microflow Engineering S.A. | Sprayer for an inhaler |
US6192876B1 (en) | 1997-12-12 | 2001-02-27 | Astra Aktiebolag | Inhalation apparatus and method |
GB2343122B (en) | 1998-10-26 | 2003-01-08 | Medic Aid Ltd | Improvements in and relating to nebulisers |
US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
US6584971B1 (en) | 1999-01-04 | 2003-07-01 | Medic-Aid Limited | Drug delivery apparatus |
US6338443B1 (en) | 1999-06-18 | 2002-01-15 | Mercury Enterprises, Inc. | High efficiency medical nebulizer |
EP1272243B1 (en) | 2000-04-11 | 2005-10-26 | Trudell Medical International | Aerosol delivery apparatus with positive expiratory pressure capacity |
US6601581B1 (en) | 2000-11-01 | 2003-08-05 | Advanced Medical Applications, Inc. | Method and device for ultrasound drug delivery |
WO2013096735A1 (en) | 2011-12-22 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Novel therapeutic agents |
WO2015157038A1 (en) * | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
-
2019
- 2019-04-03 CN CN201980064766.7A patent/CN112804993A/en active Pending
- 2019-04-03 KR KR1020217007880A patent/KR20210090607A/en unknown
- 2019-04-03 JP JP2021510120A patent/JP7377259B2/en active Active
- 2019-04-03 CA CA3109572A patent/CA3109572A1/en active Pending
- 2019-04-03 AU AU2019324330A patent/AU2019324330A1/en active Pending
- 2019-04-03 EP EP19718942.6A patent/EP3840737A1/en active Pending
- 2019-04-03 WO PCT/US2019/025538 patent/WO2020040818A1/en unknown
-
2023
- 2023-10-27 JP JP2023184364A patent/JP2024012393A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114507189A (en) * | 2021-12-08 | 2022-05-17 | 余述南 | Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis |
Also Published As
Publication number | Publication date |
---|---|
JP7377259B2 (en) | 2023-11-09 |
CA3109572A1 (en) | 2020-02-27 |
AU2019324330A1 (en) | 2021-03-04 |
JP2024012393A (en) | 2024-01-30 |
JP2021535124A (en) | 2021-12-16 |
WO2020040818A1 (en) | 2020-02-27 |
KR20210090607A (en) | 2021-07-20 |
EP3840737A1 (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112804993A (en) | Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them | |
US11116765B2 (en) | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria | |
JP2019069978A (en) | Liquid inhalation formulations comprising rpl554 | |
NO331524B1 (en) | Use of ciprofloxacin betaine for the preparation of drugs and aerosol device for administration of solid active ingredient by inhalation. | |
US20240000779A1 (en) | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | |
CN114206325A (en) | Methods and compositions for generating nitric oxide and uses thereof | |
JP6279583B2 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as Aspergillus | |
CN114828828A (en) | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses comprising them and methods of treatment | |
US10668078B2 (en) | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | |
JP2021185141A (en) | Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for treatment of sarcoidosis | |
UA125900C2 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
JP6842088B2 (en) | Composition with antifungal activity | |
US20220023282A1 (en) | Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | |
WO2019110099A1 (en) | Inhalable clofazimine formulation | |
WO2024054451A1 (en) | Method for treating nontuberculous mycobacterial infection | |
KR20220080127A (en) | Inhalable dry powder composition for lung disease | |
JP2012246228A (en) | Antimicrobial agent against legionella | |
WO2023133588A1 (en) | Methods for treating nontuberculous mycobacteria diseases | |
JP2020524172A (en) | How to reduce lung infections | |
KR20180036958A (en) | Compositions and methods for using lamellar bodies for therapeutic purposes | |
WO2023230057A1 (en) | Therapeutic useful against antimicrobial resistant agents | |
Chen | Identification of Synergistic Drug Combinations against Cystic Fibrosis Pathogens | |
WO2022256464A1 (en) | Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases | |
UA126096C2 (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |